National Biotechnology Initiative Act of 2025
- Bill Number
- S. 1387
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- Last Updated
- 2026-04-08T17:24:12Z
AI-Generated Summary
Purpose of the Legislation
The National Biotechnology Initiative Act of 2025 aims to create a coordinated federal effort to advance biotechnology—a field involving the use of living organisms or their parts for scientific and engineering purposes. The goal is to strengthen U.S. national security, boost economic productivity, and improve global competitiveness by integrating biotechnology across government activities in areas like health, agriculture, defense, and energy.
Key Provisions
- Establishment of the Initiative: The President must implement the National Biotechnology Initiative, involving 13 specified federal agencies (e.g., Departments of Agriculture, Defense, Health and Human Services) and others as needed. Agencies must coordinate on creating a national biotechnology strategy and address issues like research funding, data management, regulatory processes, workforce training, and international partnerships.
- Interagency Committee and Coordination Office:
- An Interagency Committee, with members at the Assistant Secretary level from participating agencies, oversees planning and coordination. It has three co-chairs, including the Director of the National Biotechnology Coordination Office.
- The Office, housed in the Executive Office of the President, is led by a presidentially appointed Director who advises on biotechnology policy. It handles functions like assessing security risks, supporting research, streamlining regulations, and developing bioliteracy (public understanding of biology and biotech) resources.
- The Office can convene experts without following standard advisory committee rules and receives administrative support from the National Science Foundation, with authorized funding of $22–$35 million annually from fiscal year 2026 to 2030.
- Core Activities Across Agencies:
- National Security: Analyze threats from foreign biotech developments, mitigate supply chain risks, and enhance cybersecurity for biological data.
- Research and Development: Provide ongoing funding for biotech innovation, including joint grants and tools like AI integration.
- Data and Databases: Treat biological data (information from living systems) as a national resource, standardizing it for secure, interoperable use.
- Commercialization: Support private sector product development through testbeds (facilities for scaling research), public-private partnerships, and small business programs.
- Regulatory Streamlining: Create clear pathways for approving biotech products, reducing burdens for well-understood items (e.g., those similar to natural or traditional products), with involvement from the Office of Management and Budget if disputes arise.
- Biosafety and Biosecurity: Develop plans to manage risks from biotech research, including ethical and environmental impacts.
- Workforce Development: Build skills in biotech through education, training, and fellowships, targeting students, workers, veterans, and federal employees.
- Bioliteracy: Produce plain-language resources and public engagement events to inform policymakers, innovators, and citizens.
- International Partnerships: Foster diplomacy, data-sharing agreements, and standards with allies to expand U.S. market access and counter adversaries.
- Reporting and Oversight:
- A single federal website for biotech information, including funding opportunities and regulatory guides, must launch within 540 days of enactment.
- Annual reports to Congress on activities and spending; a comprehensive national strategy every five years, covering priorities, budgets, competitiveness assessments, and data strategies.
- The Government Accountability Office (Comptroller General) will review the Initiative's effectiveness every five years for 20 years.
- After 20 years, the Office transitions to a support role for the ongoing Initiative.
Significant Changes to Existing Law
This bill introduces a new centralized framework for federal biotechnology efforts, similar to past initiatives like the National Nanotechnology Initiative but tailored to biotech. It does not directly amend specific laws but mandates new coordination mechanisms, such as the Interagency Committee and Coordination Office, to reduce overlaps in agency activities. It also requires agencies to designate biotech leads and integrate biotech into their strategies, potentially altering how existing programs (e.g., small business innovation grants) prioritize biotech. Regulatory changes focus on streamlining approvals without altering core statutes, emphasizing risk-based approaches and interagency agreements.
Potential Impacts
- On Government Agencies: Enhances coordination to avoid duplication, improves efficiency in funding and regulation, and requires new internal biotech roles, potentially increasing administrative workloads but fostering innovation across sectors like defense and health.
- On Citizens: Boosts job opportunities through workforce training, improves access to biotech products (e.g., in medicine and agriculture), and promotes public understanding via education and clear information, which could lead to safer, more ethical biotech applications.
- On International Relations: Strengthens U.S. leadership through partnerships and diplomacy, potentially easing trade barriers for U.S. exports while addressing security threats from competitors, which may influence global standards and reduce adversarial advantages in biotech.
Main Stakeholders Affected
- Federal Agencies: Participating departments (e.g., Defense, Health and Human Services, Agriculture) must realign resources and activities.
- Private Sector: Biotech companies, startups, and manufacturers benefit from commercialization support, regulatory clarity, and testbeds, but face new biosecurity requirements.
- Researchers and Educators: Universities, nonprofits, and scientists gain from funding, data tools, and workforce programs.
- Public and Workforce: Citizens, students, and workers receive training and information; veterans and industry professionals get reskilling opportunities.
- International Partners: Allies and trading nations engage in data-sharing and standards development; adversaries may face heightened scrutiny on investments.
Notable Legal, Constitutional, or Political Implications
- Legal: Exempts expert convenings from the Federal Advisory Committee Act, allowing flexible input without formal procedures. Emphasizes privacy and security for biological data, aligning with existing laws like those on genetic information but adding biotech-specific standards. The 20-year sunset for the Office ensures periodic evaluation without permanent bureaucracy.
- Constitutional: Reinforces executive branch coordination under Article II (presidential authority), while requiring congressional reporting to maintain oversight. No direct challenges to separation of powers, but regulatory streamlining could shift agency discretion toward unified pathways.
- Political: Signals bipartisan support for U.S. biotech dominance amid global competition (e.g., with China), potentially influencing future budgets and trade policies. It promotes evidence-based governance and public engagement, which could build trust but spark debates on biosecurity risks or ethical issues like genetic modification.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- 2025-04-09: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-04-09: Introduced in Senate
Bill Versions
- National Biotechnology Initiative Act of 2025 — issued 2025-04-09 — PDF (40 pages)